Chronic Shoulder Pain
Conditions
Keywords
chronic shoulder pain, spinoglenoid notch, suprascapular nerve block, suprascapular notch
Brief summary
The aim of this study is to compare the efficacy and safety of the suprascapular nerve block (SSNB) at the spinoglenoid notch with SSNB at the suprascapular notch, which is the most commonly used technique in patients with chronic shoulder pain.
Detailed description
Chronic shoulder pain (\>3 months) is one of the most common musculoskeletal problems leading to psychosocial problems. Its causes include subacromial impingement, tendinosis, calcific tendinitis, complete or partial tendon tears, adhesive capsulitis, subacromial bursitis, glenohumeral osteoarthritis, glenohumeral instability, and acromioclavicular joint pathologies. For the treatment of chronic shoulder pain, conservative or surgical methods can be applied. Suprascapular nerve block (SSNB) is an effective and safe treatment option for pain relief and increases in functional activity in these patients. The suprascapular nerve (SSN) is a peripheral nerve has both motor and sensory fibers, originates from the ventral rami of C5-C6 nerve roots. SSN passes across the posterior triangle of the neck and through the suprascapular notch enters to the supraspinous fossa. Then it comes to the infraspinous fossa via the spinoglenoid notch. The SSN has 3 sensory branches: a medial subacromial branch passes to the suprascapular notch, a lateral subacromial branch and a posterior glenohumeral branch pass the spinoglenoid notch. These branches supplies 70% of the sensory input to the shoulder. In the literature, SSNB through suprascapular notch has positive effect on shoulder functions, pain and range of motion (ROM) in patients in the treatment of chronic shoulder pain. There is no study examining the efficacy of SSNB through spinoglenoid notch in the treatment of chronic shoulder pain.Therefore, the investigators planned this randomized trial to compare of the efficiency and safety of two different SSNB techniques (approach through suprascapular notch versus spinoglenoid notch) in treatment of patients with chronic shoulder pain. Material and methods: Participants: adult patients (\>18 year old) with chronic shoulder pain Inclusion criteria: age ≥ 18 years old, shoulder pain that last more than 3 month, patients with a vas value of ≥ 4 despite treatment (drugs used for analgesia, local injections and physiotherapy methods), shoulder pain defined as non-specific shoulder pain, subacromial impingement syndrome, rotator cuff tendinopathy, adhesive capsulitis, non-traumatic instability, superior labrum anterior and posterior (SLAP) lesion, acromioclavicular pathology, shoulder osteoarthritis. Exclusion criteria: A history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, previous surgery history at the affected shoulder, shoulder injection in the last 3 months before treatment, cervical radiculopathy or myelopathy, a previous fracture close to the shoulder region, septic arthritis or local infection in the affected shoulder, anaphylaxis against local anesthetics and/or corticosteroids, cardiac pacemaker, pregnancy. Study Design: prospective, double blind, non-inferiority, randomized controlled trial Randomization method: 1:1 by computer randomization program Detail of the intervention: Experimental: SSNB through the spinoglenoid notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics Active comparator: SSNB through the suprascapular notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics Outcome measurement: Visual analogue scale of pain, active range of motion, shoulder pain and disability index (SPADI), Pain Pressure Threshold (PPT), Patient satisfaction Statistical analyses: Sample size calculation: The sample size was calculated using http://statulator.com/SampleSize/ss2M.html considering a previous study. The non-inferiority margin for SPADI was taken as 9 points. Standard deviation 15.3 (assuming normal distribution) with a power of 80, an error of 0.05 type 1; 36 patients should be enrolled per groups. Including a rate of 10% drop-out 40 patients were planned to enroll in each groups. Continuous variables 1. Student's t test: fit assumption of normal distribution 2. Mann-Whitney test: does not fit the assumption of normal distribution Categorical variables 1\. Chi-square test 2. Fisher exact test: sparse data The outcome differences within the experimental and active comparator groups of different time of evaluation will be analysed by using repeated-measures analysis of variance (ANOVA) with post hoc test with Bonferroni method.
Interventions
nerve block
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age ≥ 18 years old 2. Shoulder pain that last more than 3 month 3. Patients with a VAS value of ≥ 4 despite treatment (drugs used for analgesia, local injections and physiotherapy methods) 4. Shoulder pain defined as non-specific shoulder pain, subacromial impingement syndrome, rotator cuff tendinopathy, adhesive capsulitis, non-traumatic instability, SLAP lesion, acromioclavicular pathology, and / or shoulder osteoarthritis.
Exclusion criteria
1. A history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, and infection 2. Previous surgery history at the affected shoulder 3. Shoulder injection in the last 3 months before treatment 4. The presence of cervical radiculopathy or myelopathy 5. A previous fracture close to the shoulder region 6. Presence of septic arthritis or local infection in the affected shoulder 7. Presence of anaphylaxis against local anesthetics and / or corticosteroids 8. Presence of a cardiac pacemaker 9. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Shoulder Pain and Disability Index (SPADI) | Baseline and 1, 4, and 12 weeks after injection | Shoulder pain and disability index (SPADI). The SPADI contains 13 items that assess two domains; a 5-item subscale that measures pain and an 8-item subscale that measures disability. Each item is scored between 0 and 10, and the resulting score is converted into a 100-point scale separately for pain, disability, and total score. Increased SPADI scores indicate an increase in patients' shoulder-related pain and disability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of Visual Analog Scale (VAS) | Baseline and 1, 4, and 12 weeks after injection | The degree of shoulder pain for night and activity was assessed using Visual Analog Scale (VAS) (range 0-10) for each patient. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain. |
| Change of Range of Motion (ROM) | Baseline and 1, 4, and 12 weeks after injection | Active ROM of the affected shoulder is measured using a goniometer. These measurements included abduction, flexion, internal rotation, and external rotation. |
| Change of Pain Pressure Threshold (PPT) | Baseline and 1, 4, and 12 weeks after injection | In order to determine the pain perception thresholds in the affected shoulder, Pain Pressure Threshold (PPT) values will be calculated by taking three measurements from the middle deltoid, upper trapezius, infraspinatus and tibialis anterior area with an algometer (Commander Echo® Algometer, JTECH Medical, Midvale, UT, USA). The average of the last 2 measurements will be taken and recorded. The PPT values were expressed as kilograms per square centimeter (kg/cm2). A low PPT value represents a decrease in the pain threshold and, therefore, increased sensitivity. |
| Patient Satisfaction | Assessed at baseline and 1, 4, and 12 weeks after injection, with week 12 reported. | Patient satisfaction with the injection is determined by Likert Scale (1= very dissatisfied, 2= dissatisfied, 3=neither dissatisfied or satisfied, 4= satisfied, 5= very satisfied) |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| SSNB Through the Spinoglenoid Notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine: nerve block | 40 |
| SSNB Through the Suprascapular Notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics
US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine: nerve block | 40 |
| Total | 80 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 4 | 3 |
Baseline characteristics
| Characteristic | Total | SSNB Through the Suprascapular Notch | SSNB Through the Spinoglenoid Notch |
|---|---|---|---|
| Affected shoulder, right | 50 Participants | 24 Participants | 26 Participants |
| Age, Continuous | 57.2 years STANDARD_DEVIATION 8.7 | 57.2 years STANDARD_DEVIATION 8.2 | 57.1 years STANDARD_DEVIATION 9.3 |
| BMI, kg/m2 | 29.6 Kg/m2 STANDARD_DEVIATION 5.3 | 30 Kg/m2 STANDARD_DEVIATION 5.1 | 29.2 Kg/m2 STANDARD_DEVIATION 5.6 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 80 Participants | 40 Participants | 40 Participants |
| Sex: Female, Male Female | 56 Participants | 27 Participants | 29 Participants |
| Sex: Female, Male Male | 24 Participants | 13 Participants | 11 Participants |
| Symptom duration, months | 14.9 months STANDARD_DEVIATION 11 | 15.6 months STANDARD_DEVIATION 12.3 | 14.2 months STANDARD_DEVIATION 9.5 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 40 | 0 / 40 |
| other Total, other adverse events | 4 / 40 | 4 / 40 |
| serious Total, serious adverse events | 0 / 40 | 0 / 40 |
Outcome results
Change of Shoulder Pain and Disability Index (SPADI)
Shoulder pain and disability index (SPADI). The SPADI contains 13 items that assess two domains; a 5-item subscale that measures pain and an 8-item subscale that measures disability. Each item is scored between 0 and 10, and the resulting score is converted into a 100-point scale separately for pain, disability, and total score. Increased SPADI scores indicate an increase in patients' shoulder-related pain and disability.
Time frame: Baseline and 1, 4, and 12 weeks after injection
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 4th week) | 27.0 score on a scale | Standard Deviation 22.2 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 12th week) | 30.3 score on a scale | Standard Deviation 26 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 1st week) | 25.9 score on a scale | Standard Deviation 22.2 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 1st week) | 20.3 score on a scale | Standard Deviation 20.3 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 12th week) | 29.4 score on a scale | Standard Deviation 23 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 4th week) | 26.0 score on a scale | Standard Deviation 22.3 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 4th week) | 29.4 score on a scale | Standard Deviation 24.1 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 12th week) | 29.6 score on a scale | Standard Deviation 22.1 |
| SSNB Through the Spinoglenoid Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 1st week) | 22.1 score on a scale | Standard Deviation 20.3 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 12th week) | 33.0 score on a scale | Standard Deviation 29.2 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 1st week) | 25.9 score on a scale | Standard Deviation 23.7 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 4th week) | 36.6 score on a scale | Standard Deviation 22 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI- Total (Baseline- 12th week) | 34.1 score on a scale | Standard Deviation 28.1 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 1st week) | 27.5 score on a scale | Standard Deviation 24.4 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 4th week) | 37.6 score on a scale | Standard Deviation 21.7 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Pain (Baseline - 12th week) | 35.7 score on a scale | Standard Deviation 28.6 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 1st week) | 24.8 score on a scale | Standard Deviation 24.5 |
| SSNB Through the Suprascapular Notch | Change of Shoulder Pain and Disability Index (SPADI) | SPADI - Disability (Baseline - 4th week) | 35.8 score on a scale | Standard Deviation 23.8 |
Change of Pain Pressure Threshold (PPT)
In order to determine the pain perception thresholds in the affected shoulder, Pain Pressure Threshold (PPT) values will be calculated by taking three measurements from the middle deltoid, upper trapezius, infraspinatus and tibialis anterior area with an algometer (Commander Echo® Algometer, JTECH Medical, Midvale, UT, USA). The average of the last 2 measurements will be taken and recorded. The PPT values were expressed as kilograms per square centimeter (kg/cm2). A low PPT value represents a decrease in the pain threshold and, therefore, increased sensitivity.
Time frame: Baseline and 1, 4, and 12 weeks after injection
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-1st week) | -0.3 kg/cm2 | Standard Deviation 1.5 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-4th week) | -0.1 kg/cm2 | Standard Deviation 1.2 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-12th week) | -0.2 kg/cm2 | Standard Deviation 1.4 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-1st week) | -0.2 kg/cm2 | Standard Deviation 1 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-4th week) | 0.0 kg/cm2 | Standard Deviation 1.5 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-12th week) | -0.2 kg/cm2 | Standard Deviation 1.6 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-1st week) | -0.3 kg/cm2 | Standard Deviation 1.4 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-4th week) | 0.0 kg/cm2 | Standard Deviation 1.9 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-12th week) | -0.4 kg/cm2 | Standard Deviation 1.7 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-1st week) | -0.3 kg/cm2 | Standard Deviation 2.3 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-4th week) | -0.1 kg/cm2 | Standard Deviation 1.9 |
| SSNB Through the Spinoglenoid Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-12th week) | -0.4 kg/cm2 | Standard Deviation 1.7 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-4th week) | 0.1 kg/cm2 | Standard Deviation 1.8 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-1st week) | 0.0 kg/cm2 | Standard Deviation 1.5 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-1st week) | -0.1 kg/cm2 | Standard Deviation 1.6 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-4th week) | -0.4 kg/cm2 | Standard Deviation 1.4 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-1st week) | -0.2 kg/cm2 | Standard Deviation 1.4 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - upper trapezius (Baseline-12th week) | -0.3 kg/cm2 | Standard Deviation 1.3 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-4th week) | -0.2 kg/cm2 | Standard Deviation 1.6 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-1st week) | 0.3 kg/cm2 | Standard Deviation 1.5 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Tibialis Anterior (Baseline-12th week) | -0.4 kg/cm2 | Standard Deviation 1.5 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-4th week) | 0.1 kg/cm2 | Standard Deviation 1.8 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - Infraspinatus (Baseline-12th week) | -0.2 kg/cm2 | Standard Deviation 1.7 |
| SSNB Through the Suprascapular Notch | Change of Pain Pressure Threshold (PPT) | PPT - middle deltoid (Baseline-12th week) | -0.2 kg/cm2 | Standard Deviation 1.6 |
Change of Range of Motion (ROM)
Active ROM of the affected shoulder is measured using a goniometer. These measurements included abduction, flexion, internal rotation, and external rotation.
Time frame: Baseline and 1, 4, and 12 weeks after injection
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 1st week) | -3.9 degree | Standard Deviation 16 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 4th week) | -8.6 degree | Standard Deviation 18.3 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 12th week) | -8.8 degree | Standard Deviation 18.1 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 1st week) | -4.8 degree | Standard Deviation 14.4 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 4th week) | -14.1 degree | Standard Deviation 24.9 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 12th week) | -13.0 degree | Standard Deviation 27.7 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 1st week) | 0.9 degree | Standard Deviation 4.7 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 4th week) | -0.9 degree | Standard Deviation 3.2 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 12th week) | -2.4 degree | Standard Deviation 7 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 1st week) | -2.5 degree | Standard Deviation 6.9 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 4th week) | -6.0 degree | Standard Deviation 8.9 |
| SSNB Through the Spinoglenoid Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 12th week) | -8.5 degree | Standard Deviation 12.3 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 4th week) | -10.9 degree | Standard Deviation 16 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 1st week) | -9.6 degree | Standard Deviation 14 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 1st week) | -4.5 degree | Standard Deviation 9.7 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 4th week) | -18.6 degree | Standard Deviation 21.2 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 1st week) | -6.8 degree | Standard Deviation 17.3 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM flexion (Baseline- 12th week) | -20.5 degree | Standard Deviation 22.2 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 4th week) | -7.5 degree | Standard Deviation 11.9 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 1st week) | -9.6 degree | Standard Deviation 16.1 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM external rotation (Baseline- 12th week) | -10.0 degree | Standard Deviation 20.3 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 4th week) | -23.9 degree | Standard Deviation 30.1 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM internal rotation (Baseline- 12th week) | -8.6 degree | Standard Deviation 12.2 |
| SSNB Through the Suprascapular Notch | Change of Range of Motion (ROM) | ROM abduction (Baseline- 12th week) | -26.0 degree | Standard Deviation 29.1 |
Change of Visual Analog Scale (VAS)
The degree of shoulder pain for night and activity was assessed using Visual Analog Scale (VAS) (range 0-10) for each patient. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain.
Time frame: Baseline and 1, 4, and 12 weeks after injection
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 1st week) | 2.2 score on a scale | Standard Deviation 2.5 |
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 4st week) | 2.8 score on a scale | Standard Deviation 2.7 |
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 12th week) | 2.9 score on a scale | Standard Deviation 2.7 |
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 1st week) | 3.2 score on a scale | Standard Deviation 2.6 |
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 4st week) | 3.4 score on a scale | Standard Deviation 2.6 |
| SSNB Through the Spinoglenoid Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 12th week) | 3.1 score on a scale | Standard Deviation 2.7 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 4st week) | 3.9 score on a scale | Standard Deviation 2.4 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 1st week) | 2.8 score on a scale | Standard Deviation 2.5 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 1st week) | 3.0 score on a scale | Standard Deviation 2.9 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 4st week) | 3.7 score on a scale | Standard Deviation 2.4 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Night (Baseline - 12th week) | 3.3 score on a scale | Standard Deviation 3.2 |
| SSNB Through the Suprascapular Notch | Change of Visual Analog Scale (VAS) | VAS Activity (Baseline - 12th week) | 3.5 score on a scale | Standard Deviation 2.9 |
Patient Satisfaction
Patient satisfaction with the injection is determined by Likert Scale (1= very dissatisfied, 2= dissatisfied, 3=neither dissatisfied or satisfied, 4= satisfied, 5= very satisfied)
Time frame: Assessed at baseline and 1, 4, and 12 weeks after injection, with week 12 reported.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| SSNB Through the Spinoglenoid Notch | Patient Satisfaction | Dissatisfied | 8 Participants |
| SSNB Through the Spinoglenoid Notch | Patient Satisfaction | Satisfied | 12 Participants |
| SSNB Through the Spinoglenoid Notch | Patient Satisfaction | neither dissatisfied or satisfied | 3 Participants |
| SSNB Through the Spinoglenoid Notch | Patient Satisfaction | Extremely satisfied | 14 Participants |
| SSNB Through the Spinoglenoid Notch | Patient Satisfaction | Extremely dissatisfied | 3 Participants |
| SSNB Through the Suprascapular Notch | Patient Satisfaction | Extremely satisfied | 20 Participants |
| SSNB Through the Suprascapular Notch | Patient Satisfaction | Extremely dissatisfied | 2 Participants |
| SSNB Through the Suprascapular Notch | Patient Satisfaction | Dissatisfied | 1 Participants |
| SSNB Through the Suprascapular Notch | Patient Satisfaction | neither dissatisfied or satisfied | 6 Participants |
| SSNB Through the Suprascapular Notch | Patient Satisfaction | Satisfied | 11 Participants |